These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 16302826

  • 1. Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.
    Quattropani A, Dorbais J, Covini D, Pittet PA, Colovray V, Thomas RJ, Coxhead R, Halazy S, Scheer A, Missotten M, Ayala G, Bradshaw C, De Raemy-Schenk AM, Nichols A, Cirillo R, Tos EG, Giachetti C, Golzio L, Marinelli P, Church DJ, Barberis C, Chollet A, Schwarz MK.
    J Med Chem; 2005 Dec 01; 48(24):7882-905. PubMed ID: 16302826
    [Abstract] [Full Text] [Related]

  • 2. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
    Cirillo R, Gillio Tos E, Schwarz MK, Quattropani A, Scheer A, Missotten M, Dorbais J, Nichols A, Borrelli F, Giachetti C, Golzio L, Marinelli P, Thomas RJ, Chevillard C, Laurent F, Portet K, Barberis C, Chollet A.
    J Pharmacol Exp Ther; 2003 Jul 01; 306(1):253-61. PubMed ID: 12660315
    [Abstract] [Full Text] [Related]

  • 3. SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor.
    Serradeil-Le Gal C, Valette G, Foulon L, Germain G, Advenier C, Naline E, Bardou M, Martinolle JP, Pouzet B, Raufaste D, Garcia C, Double-Cazanave E, Pauly M, Pascal M, Barbier A, Scatton B, Maffrand JP, Le Fur G.
    J Pharmacol Exp Ther; 2004 Apr 01; 309(1):414-24. PubMed ID: 14722330
    [Abstract] [Full Text] [Related]

  • 4. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
    Borthwick AD, Davies DE, Exall AM, Livermore DG, Sollis SL, Nerozzi F, Allen MJ, Perren M, Shabbir SS, Woollard PM, Wyatt PG.
    J Med Chem; 2005 Nov 03; 48(22):6956-69. PubMed ID: 16250654
    [Abstract] [Full Text] [Related]

  • 5. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
    Chan WY, Wo NC, Cheng LL, Manning M.
    J Pharmacol Exp Ther; 1996 May 03; 277(2):999-1003. PubMed ID: 8627583
    [Abstract] [Full Text] [Related]

  • 6. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.
    Borthwick AD, Davies DE, Exall AM, Hatley RJ, Hughes JA, Irving WR, Livermore DG, Sollis SL, Nerozzi F, Valko KL, Allen MJ, Perren M, Shabbir SS, Woollard PM, Price MA.
    J Med Chem; 2006 Jul 13; 49(14):4159-70. PubMed ID: 16821776
    [Abstract] [Full Text] [Related]

  • 7. Vasopressin and oxytocin in normal reproduction and in the pathophysiology of preterm labour and primary dysmenorrhoea. Development of receptor antagonists for therapeutic use in these conditions.
    Akerlund M.
    Rocz Akad Med Bialymst; 2004 Jul 13; 49():18-21. PubMed ID: 15631309
    [Abstract] [Full Text] [Related]

  • 8. Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.
    Scott JD, Miller MW, Li SW, Lin SI, Vaccaro HA, Hong L, Mullins DE, Guzzi M, Weinstein J, Hodgson RA, Varty GB, Stamford AW, Chan TY, McKittrick BA, Greenlee WJ, Priestley T, Parker EM.
    Bioorg Med Chem Lett; 2009 Nov 01; 19(21):6018-22. PubMed ID: 19800231
    [Abstract] [Full Text] [Related]

  • 9. Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.
    McCafferty GP, Pullen MA, Wu C, Edwards RM, Allen MJ, Woollard PM, Borthwick AD, Liddle J, Hickey DM, Brooks DP, Westfall TD.
    Am J Physiol Regul Integr Comp Physiol; 2007 Jul 01; 293(1):R299-305. PubMed ID: 17395790
    [Abstract] [Full Text] [Related]

  • 10. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A, Murat B, Trueba M, Ventura MA, Wo NC, Szeto HH, Cheng LL, Stoev S, Guillon G, Manning M.
    J Med Chem; 2007 Feb 22; 50(4):835-47. PubMed ID: 17300166
    [Abstract] [Full Text] [Related]

  • 11. Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
    Bell IM, Erb JM, Freidinger RM, Gallicchio SN, Guare JP, Guidotti MT, Halpin RA, Hobbs DW, Homnick CF, Kuo MS, Lis EV, Mathre DJ, Michelson SR, Pawluczyk JM, Pettibone DJ, Reiss DR, Vickers S, Williams PD, Woyden CJ.
    J Med Chem; 1998 Jun 04; 41(12):2146-63. PubMed ID: 9622556
    [Abstract] [Full Text] [Related]

  • 12. Arrest of preterm labor in rat and mouse by an oral and selective nonprostanoid antagonist of the prostaglandin F2alpha receptor (FP).
    Cirillo R, Tos EG, Page P, Missotten M, Quattropani A, Scheer A, Schwarz MK, Chollet A.
    Am J Obstet Gynecol; 2007 Jul 04; 197(1):54.e1-9. PubMed ID: 17618756
    [Abstract] [Full Text] [Related]

  • 13. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 Jul 04; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 14. Profile of an oxytocin antagonist, RWJ 22164 for treatment of preterm labor in laboratory models of uterine contractility.
    Demarest KT, Hahn DW, Ericson E, Capetola RJ, Fuchs AR, McGuire JL.
    Am J Perinatol; 1989 Apr 04; 6(2):200-4. PubMed ID: 2712917
    [Abstract] [Full Text] [Related]

  • 15. Barusiban suppresses oxytocin-induced preterm labour in non-human primates.
    Reinheimer TM.
    BMC Pregnancy Childbirth; 2007 Jun 01; 7 Suppl 1(Suppl 1):S15. PubMed ID: 17570159
    [Abstract] [Full Text] [Related]

  • 16. Introduction of a cis-prolyl mimic in position 7 of the peptide hormone oxytocin does not result in antagonistic activity.
    Wittelsberger A, Patiny L, Slaninova J, Barberis C, Mutter M.
    J Med Chem; 2005 Oct 20; 48(21):6553-62. PubMed ID: 16220972
    [Abstract] [Full Text] [Related]

  • 17. Progress in the development of oxytocin antagonists for use in preterm labor.
    Williams PD, Bock MG, Evans BE, Freidinger RM, Pettibone DJ.
    Adv Exp Med Biol; 1998 Oct 20; 449():473-9. PubMed ID: 10026841
    [Abstract] [Full Text] [Related]

  • 18. Oxytocin and vasopressin V(1A) receptors as new therapeutic targets in assisted reproduction.
    Pierzynski P.
    Reprod Biomed Online; 2011 Jan 20; 22(1):9-16. PubMed ID: 21130036
    [Abstract] [Full Text] [Related]

  • 19. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
    Murugesan N, Gu Z, Spergel S, Young M, Chen P, Mathur A, Leith L, Hermsmeier M, Liu EC, Zhang R, Bird E, Waldron T, Marino A, Koplowitz B, Humphreys WG, Chong S, Morrison RA, Webb ML, Moreland S, Trippodo N, Barrish JC.
    J Med Chem; 2003 Jan 02; 46(1):125-37. PubMed ID: 12502366
    [Abstract] [Full Text] [Related]

  • 20. Identification of an orally active, nonpeptidyl oxytocin antagonist.
    Pettibone DJ, Clineschmidt BV, Kishel MT, Lis EV, Reiss DR, Woyden CJ, Evans BE, Freidinger RM, Veber DF, Cook MJ.
    J Pharmacol Exp Ther; 1993 Jan 02; 264(1):308-14. PubMed ID: 8423533
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.